Paediatric Drugs · 4 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This narrative review examines conventional and novel topical therapies for pediatric psoriasis, including the recently FDA-approved non-steroidal agents roflumilast and tapinarof, as well as emerging treatments targeting new pathogenic pathways.
This narrative review synthesizes current evidence on topical treatments for pediatric psoriasis, covering conventional agents such as corticosteroids, calcineurin inhibitors, vitamin D analogs, anthralin, and coal tar, as well as novel non-steroidal therapies. Conventional treatments are noted to have limitations related to side effects, tolerability, and efficacy, particularly for children and sensitive body areas. Two newly FDA-approved topical agents are highlighted: roflumilast, a phosphodiesterase type 4 inhibitor approved for plaque psoriasis in patients aged 12 years and older, and tapinarof, an aryl hydrocarbon receptor modulator approved for adult psoriasis with ongoing pediatric studies. The review notes that pediatric psoriasis is increasing in prevalence and that novel topical agents provide promising options for improving clinical outcomes and quality of life.
